Ad is loading...
FATE
Price
$2.02
Change
-$0.06 (-2.88%)
Updated
Nov 15 closing price
106 days until earnings call
MRKR
Price
$3.07
Change
-$0.43 (-12.29%)
Updated
Nov 15 closing price
Ad is loading...

FATE vs MRKR

Header iconFATE vs MRKR Comparison
Open Charts FATE vs MRKRBanner chart's image
Fate Therapeutics
Price$2.02
Change-$0.06 (-2.88%)
Volume$1.75M
CapitalizationN/A
Marker Therapeutics
Price$3.07
Change-$0.43 (-12.29%)
Volume$43.94K
CapitalizationN/A
FATE vs MRKR Comparison Chart
Loading...
FATE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
MRKR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
FATE vs. MRKR commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a Sell and MRKR is a Sell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (FATE: $2.02 vs. MRKR: $3.07)
Brand notoriety: FATE and MRKR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FATE: 137% vs. MRKR: 117%
Market capitalization -- FATE: $230.07M vs. MRKR: $27.39M
FATE [@Biotechnology] is valued at $230.07M. MRKR’s [@Biotechnology] market capitalization is $27.39M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green whileMRKR’s FA Score has 0 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • MRKR’s FA Score: 0 green, 5 red.
According to our system of comparison, MRKR is a better buy in the long-term than FATE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 4 TA indicator(s) are bullish while MRKR’s TA Score has 4 bullish TA indicator(s).

  • FATE’s TA Score: 4 bullish, 4 bearish.
  • MRKR’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, FATE is a better buy in the short-term than MRKR.

Price Growth

FATE (@Biotechnology) experienced а -16.53% price change this week, while MRKR (@Biotechnology) price change was -25.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

FATE is expected to report earnings on Mar 03, 2025.

MRKR is expected to report earnings on May 11, 2023.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($230M) has a higher market cap than MRKR($27.4M). MRKR (-44.182) and FATE (-45.989) have similar YTD gains . MRKR has higher annual earnings (EBITDA): -10.99M vs. FATE (-176.34M). FATE has more cash in the bank: 305M vs. MRKR (7.8M). MRKR has less debt than FATE: MRKR (0) vs FATE (101M). FATE has higher revenues than MRKR: FATE (12.3M) vs MRKR (0).
FATEMRKRFATE / MRKR
Capitalization230M27.4M839%
EBITDA-176.34M-10.99M1,604%
Gain YTD-45.989-44.182104%
P/E RatioN/AN/A-
Revenue12.3M0-
Total Cash305M7.8M3,910%
Total Debt101M0-
FUNDAMENTALS RATINGS
FATE vs MRKR: Fundamental Ratings
FATE
MRKR
OUTLOOK RATING
1..100
5981
VALUATION
overvalued / fair valued / undervalued
1..100
19
Undervalued
39
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9596
PRICE GROWTH RATING
1..100
9363
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (19) in the Biotechnology industry is in the same range as MRKR (39) in the Other Consumer Services industry. This means that FATE’s stock grew similarly to MRKR’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MRKR (100) in the Other Consumer Services industry. This means that FATE’s stock grew similarly to MRKR’s over the last 12 months.

FATE's SMR Rating (95) in the Biotechnology industry is in the same range as MRKR (96) in the Other Consumer Services industry. This means that FATE’s stock grew similarly to MRKR’s over the last 12 months.

MRKR's Price Growth Rating (63) in the Other Consumer Services industry is in the same range as FATE (93) in the Biotechnology industry. This means that MRKR’s stock grew similarly to FATE’s over the last 12 months.

MRKR's P/E Growth Rating (100) in the Other Consumer Services industry is in the same range as FATE (100) in the Biotechnology industry. This means that MRKR’s stock grew similarly to FATE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FATEMRKR
RSI
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
86%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 14 days ago
86%
Bullish Trend 11 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
View a ticker or compare two or three
Ad is loading...
FATE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
MRKR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ANY1.490.04
+2.76%
Sphere 3D Corp
VBTX29.27-0.14
-0.48%
Veritex Holdings
NXDT5.48-0.11
-1.97%
NexPoint Diversified Real Estate Trust
ANSS332.38-7.90
-2.32%
ANSYS
RARE44.75-2.89
-6.07%
Ultragenyx Pharmaceutical

MRKR and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRKR has been loosely correlated with CGTX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if MRKR jumps, then CGTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRKR
1D Price
Change %
MRKR100%
-12.29%
CGTX - MRKR
36%
Loosely correlated
-9.85%
INTS - MRKR
28%
Poorly correlated
-0.79%
FATE - MRKR
27%
Poorly correlated
-2.88%
SNPX - MRKR
27%
Poorly correlated
-8.05%
UNCY - MRKR
27%
Poorly correlated
+2.68%
More